436 related articles for article (PubMed ID: 26852185)
61. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.
Nobili V; Alisi A; Musso G; Scorletti E; Calder PC; Byrne CD
Crit Rev Clin Lab Sci; 2016; 53(2):106-20. PubMed ID: 26463349
[TBL] [Abstract][Full Text] [Related]
62. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
[TBL] [Abstract][Full Text] [Related]
63. Association between Dietary Vitamin C Intake and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Middle-Aged and Older Adults.
Wei J; Lei GH; Fu L; Zeng C; Yang T; Peng SF
PLoS One; 2016; 11(1):e0147985. PubMed ID: 26824361
[TBL] [Abstract][Full Text] [Related]
64. Dietary supplementation in patients with alcoholic liver disease: a review on current evidence.
Ghorbani Z; Hajizadeh M; Hekmatdoost A
Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):348-60. PubMed ID: 27498574
[TBL] [Abstract][Full Text] [Related]
65. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
66. Diagnosis and management of non-alcoholic fatty liver disease.
Jennison E; Patel J; Scorletti E; Byrne CD
Postgrad Med J; 2019 Jun; 95(1124):314-322. PubMed ID: 31085617
[TBL] [Abstract][Full Text] [Related]
67. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
[TBL] [Abstract][Full Text] [Related]
68. A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease.
Panera N; Barbaro B; Della Corte C; Mosca A; Nobili V; Alisi A
Nutr Res; 2018 Oct; 58():1-16. PubMed ID: 30340810
[TBL] [Abstract][Full Text] [Related]
69. Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.
Cui CX; Deng JN; Yan L; Liu YY; Fan JY; Mu HN; Sun HY; Wang YH; Han JY
J Ethnopharmacol; 2017 Aug; 208():24-35. PubMed ID: 28648927
[TBL] [Abstract][Full Text] [Related]
70. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals.
Della Pepa G; Vetrani C; Lombardi G; Bozzetto L; Annuzzi G; Rivellese AA
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28954437
[TBL] [Abstract][Full Text] [Related]
71. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis.
Polimeni L; Del Ben M; Baratta F; Perri L; Albanese F; Pastori D; Violi F; Angelico F
World J Hepatol; 2015 Jun; 7(10):1325-36. PubMed ID: 26052378
[TBL] [Abstract][Full Text] [Related]
72. Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis.
Lee CH; Fu Y; Yang SJ; Chi CC
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32932796
[TBL] [Abstract][Full Text] [Related]
73. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.
Musso G; Gambino R; Cassader M; Pagano G
Hepatology; 2010 Jul; 52(1):79-104. PubMed ID: 20578268
[TBL] [Abstract][Full Text] [Related]
74. Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats.
Tan Y; Kim J; Cheng J; Ong M; Lao WG; Jin XL; Lin YG; Xiao L; Zhu XQ; Qu XQ
World J Gastroenterol; 2017 Jun; 23(21):3805-3814. PubMed ID: 28638220
[TBL] [Abstract][Full Text] [Related]
75. The Role of Vitamins in Non-Alcoholic Fatty Liver Disease: A Systematic Review.
Abe RAM; Masroor A; Khorochkov A; Prieto J; Singh KB; Nnadozie MC; Abdal M; Shrestha N; Mohammed L
Cureus; 2021 Aug; 13(8):e16855. PubMed ID: 34522493
[TBL] [Abstract][Full Text] [Related]
76. Dietary lipids and NAFLD: suggestions for improved nutrition.
Molendi-Coste O; Legry V; Leclercq IA
Acta Gastroenterol Belg; 2010; 73(4):431-6. PubMed ID: 21299150
[TBL] [Abstract][Full Text] [Related]
77. Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial.
de Avelar CR; Nunes BVC; da Silva Sassaki B; Dos Santos Vasconcelos M; de Oliveira LPM; Lyra AC; Bueno AA; de Jesus RP
Trials; 2023 Mar; 24(1):177. PubMed ID: 36899430
[TBL] [Abstract][Full Text] [Related]
78. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP).
Rizzo M; Colletti A; Penson PE; Katsiki N; Mikhailidis DP; Toth PP; Gouni-Berthold I; Mancini J; Marais D; Moriarty P; Ruscica M; Sahebkar A; Vinereanu D; Cicero AFG; Banach M;
Pharmacol Res; 2023 Mar; 189():106679. PubMed ID: 36764041
[TBL] [Abstract][Full Text] [Related]
79. Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice.
Presa N; Clugston RD; Lingrell S; Kelly SE; Merrill AH; Jana S; Kassiri Z; Gómez-Muñoz A; Vance DE; Jacobs RL; van der Veen JN
Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):14-25. PubMed ID: 30300671
[TBL] [Abstract][Full Text] [Related]
80. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
